Results 131 to 140 of about 2,475,393 (270)

In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus. [PDF]

Iran J Pharm Res, 2020
Sewidan N, Abu Khalaf R, Mohammad H, Hammad W.   +3 more
europepmc   +1 more source

Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors.

, 2012
Dipeptidyl peptidase IV (DPPIV, DPP4) is a serine protease that releases N-terminal dipeptides. It is a validated drug target for type 2 diabetes and DPPIV inhibitors are currently evaluated for other therapeutic applications. Various assays are used for
Gomez, Nelson, Simon Scharpé, Veerle Matheeussen, De Meester, Ingrid, Matheeussen, Veerle, Van der Veken, Pieter, Nelson Gomez, Jungraithmayr, Wolfgang, Scharpé, Simon, Anne-Marie Lambeir, Gomez Malaver, Nelson, Pieter Van der Veken, Kathleen Mc Entee, McEntee, Kathleen, Lambeir, Anne-Marie, Ingrid De Meester, Wolfgang Jungraithmayr   +16 more
core   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

Medicinal Research Reviews, Volume 46, Issue 6, Page 1574-1602, November 2026.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Class effect beyond glucose: Implications of the LEGEND‐T2DM findings for cardiovascular outcomes

Journal of Diabetes Investigation, EarlyView.
Yuexing Liu, Weiping Jia
wiley   +1 more source

Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation

Medicinal Research Reviews, Volume 46, Issue 6, Page 1939-1957, November 2026.
ABSTRACT The Nav1.5 channel, a major isoform of voltage‐gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac ...
Arkapravo Chattopadhyay, Lynn C. Lunsonga, Peter E. Light, Khaled Barakat   +3 more
wiley   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10318-10329, November 2026.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10210-10217, November 2026.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

A comprehensive study of ground-roasted coffee beans from Coffea liberica as dipeptidyl peptidase IV inhibitors

European Pharmaceutical Journal
Type 2 diabetes mellitus (T2DM), a degenerative disease characterized by insulin resistance, has been reported as a serious healthcare problem, especially in low-to-middle-income countries.
Riswanto Florentinus Dika Octa, Adventra Nicolaus De Deo, Priyambodo Gregorius Seno, Kusraynaldi Titus Marcel, Br Sembiring Angel Yemima Srininta, Larasati Theresia Niken, Windarsih Anjar, Wira Waskitha Stephanus Satria, Gani Michael Raharja, Istyastono Enade Perdana   +9 more
doaj   +1 more source

Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review

, 2018
Diabetes mellitus is an increasing public health problem in the world. Type 2 diabetes is the most common type of diabetes whose complications contribute to its high death rate.
Hongwei Gao, Madina Kabas, Gulmira Turdu, Yingying Jiang   +3 more
core   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source